| Schedule of reportable segments net revenue and net loss |
The Company's reportable segments' net revenues and net loss for the three and six months ended June 30, 2026 and 2025, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Six Months Ended |
|
(in thousands) |
|
June 30, 2026 |
|
|
June 30, 2025 |
|
|
|
(unaudited) |
|
|
(unaudited) |
|
|
|
Human Health |
|
|
Animal Health |
|
|
Total |
|
|
Human Health |
|
|
Animal Health |
|
|
Total |
|
External revenue |
|
$ |
|
21,102 |
|
|
|
|
395 |
|
|
$ |
|
21,497 |
|
|
$ |
|
5,001 |
|
|
$ |
|
192 |
|
|
$ |
|
5,193 |
|
Less: Segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue |
|
|
|
1,947 |
|
|
|
|
242 |
|
|
|
|
2,189 |
|
|
|
|
1,023 |
|
|
|
|
19 |
|
|
|
|
1,042 |
|
Research and development |
|
|
|
6,005 |
|
|
|
|
1,250 |
|
|
|
|
7,255 |
|
|
|
|
5,714 |
|
|
|
|
1,281 |
|
|
|
|
6,995 |
|
Sales and marketing |
|
|
|
658 |
|
|
|
|
243 |
|
|
|
|
901 |
|
|
|
|
4,697 |
|
|
|
|
263 |
|
|
|
|
4,960 |
|
General and administrative |
|
|
|
3,914 |
|
|
|
|
5,664 |
|
|
|
|
9,578 |
|
|
|
|
4,003 |
|
|
|
|
6,579 |
|
|
|
|
10,582 |
|
Interest |
|
|
|
346 |
|
|
|
|
514 |
|
|
|
|
860 |
|
|
|
|
1 |
|
|
|
|
(72 |
) |
|
|
|
(71 |
) |
Other segment items* |
|
|
|
986 |
|
|
|
|
5,733 |
|
|
|
|
6,719 |
|
|
|
|
465 |
|
|
|
|
3,776 |
|
|
|
|
4,241 |
|
Segment expenses |
|
|
|
13,856 |
|
|
|
|
13,646 |
|
|
|
|
27,502 |
|
|
|
|
15,903 |
|
|
|
|
11,846 |
|
|
|
|
27,749 |
|
Segment net comprehensive income (loss) |
|
$ |
|
7,246 |
|
|
$ |
|
(13,251 |
) |
|
$ |
|
(6,005 |
) |
|
$ |
|
(10,902 |
) |
|
$ |
|
(11,654 |
) |
|
$ |
|
(22,556 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of net comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments and reconciling items** |
|
|
|
|
|
|
|
|
|
|
|
1,469 |
|
|
|
|
|
|
|
|
|
|
|
|
1,115 |
|
Consolidated net comprehensive loss |
|
|
|
|
|
|
|
|
|
$ |
|
(4,536 |
) |
|
|
|
|
|
|
|
|
|
$ |
|
(21,441 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Three Months Ended |
|
(in thousands) |
|
June 30, 2026 |
|
|
June 30, 2025 |
|
|
|
(unaudited) |
|
|
(unaudited) |
|
|
|
Human Health |
|
|
Animal Health |
|
|
Total |
|
|
Human Health |
|
|
Animal Health |
|
|
Total |
|
External revenue |
|
$ |
|
1,175 |
|
|
$ |
|
50 |
|
|
$ |
|
1,225 |
|
|
$ |
|
2,863 |
|
|
$ |
|
116 |
|
|
$ |
|
2,979 |
|
Less: Segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue |
|
|
|
960 |
|
|
|
|
71 |
|
|
|
|
1,031 |
|
|
|
|
517 |
|
|
|
|
10 |
|
|
|
|
527 |
|
Research and development |
|
|
|
2,836 |
|
|
|
|
495 |
|
|
|
|
3,331 |
|
|
|
|
2,600 |
|
|
|
|
669 |
|
|
|
|
3,269 |
|
Sales and marketing |
|
|
|
(45 |
) |
|
|
|
50 |
|
|
|
|
5 |
|
|
|
|
2,301 |
|
|
|
|
166 |
|
|
|
|
2,467 |
|
General and administrative |
|
|
|
1,943 |
|
|
|
|
3,022 |
|
|
|
|
4,965 |
|
|
|
|
2,000 |
|
|
|
|
3,242 |
|
|
|
|
5,242 |
|
Interest |
|
|
|
159 |
|
|
|
|
2 |
|
|
|
|
161 |
|
|
|
|
— |
|
|
|
|
(15 |
) |
|
|
|
(15 |
) |
Other segment items* |
|
|
|
(57 |
) |
|
|
|
5,392 |
|
|
|
|
5,335 |
|
|
|
|
155 |
|
|
|
|
2,600 |
|
|
|
|
2,755 |
|
Segment expenses |
|
|
|
5,796 |
|
|
|
|
9,032 |
|
|
|
|
14,828 |
|
|
|
|
7,573 |
|
|
|
|
6,672 |
|
|
|
|
14,245 |
|
Segment net comprehensive loss |
|
$ |
|
(4,621 |
) |
|
$ |
|
(8,982 |
) |
|
$ |
|
(13,603 |
) |
|
$ |
|
(4,710 |
) |
|
$ |
|
(6,556 |
) |
|
$ |
|
(11,266 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of net comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments and reconciling items** |
|
|
|
|
|
|
|
|
|
|
|
802 |
|
|
|
|
|
|
|
|
|
|
|
|
684 |
|
Consolidated net comprehensive loss |
|
|
|
|
|
|
|
|
|
$ |
|
(12,801 |
) |
|
|
|
|
|
|
|
|
|
$ |
|
(10,582 |
) |
*Other segment items for each reportable segment include: •Human Health - realized gain/loss on foreign exchange transactions and change in fair value of warrants. •Animal Health - realized and unrealized gain/loss on foreign exchange transactions, change in fair value of warrants, gain/loss on debt extinguishment and share in net income or loss in joint venture. **Adjustments and reconciling items include intercompany elimination entries
|